Developing Pharmaceutical Clinical Research Support Into a New Core Revenue Stream
First written in FY2016. 2 of 29 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2024.
The whole theme swung hardest in 2020: 1 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual report
「The pharmaceutical clinical research support business was discontinued at the end of the current consolidated fiscal year.」
The pharmaceutical clinical research support business, which had been developed as a new source of revenue, was discontinued at the end of the current consolidated fiscal year. - FY2024-Q3Revenue and orders received continued to declineAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥102 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 59.0% year on year. Orders received totaled ¥55 million, down 64.7% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥41 million, down 71.1% from the end of the same period of the previous year.」
Revenue, orders received and the order backlog in the pharmaceutical clinical research support business all fell below the same period of the previous year. The substantial decline in the order backlog has continued. - FY2024-Q2Revenue declined, orders received fell, and the decline in the order backlog widenedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥110 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 27.1% year on year. Orders received totaled ¥63 million, down 12.4% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥42 million, down 73.3% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue, orders received and the order backlog all fell below the same period of the previous year, with the decline in the order backlog widening particularly. The accumulation of future revenue as a new source of revenue is weakening. - FY2024-Q1Revenue increased, but the decline in orders received and the order backlog widenedAnnual report
「We recognized revenue of ¥43 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 38.1% year on year. Orders received totaled ¥18 million, down 57.3% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥63 million, down 69.6% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue, orders received and the order backlog all fell below the same period of the previous year, and the decline in the order backlog widened. - FY2023Revenue increased, but the decline in orders received and the order backlog widenedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥356 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 24.9% from the previous fiscal year. Orders received totaled ¥209 million, down 25.9% from the previous fiscal year, while the order backlog at the end of the current consolidated fiscal year was ¥88 million, down 62.5% from the end of the previous fiscal year.」
Full-year revenue increased, while orders received and the order backlog declined, with the decline in the order backlog widening particularly from the previous fiscal year. - FY2023-Q3Revenue increased, but the decline in orders received and the order backlog widenedAnnual report
「We recognized revenue of ¥250 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 14.4% year on year. Orders received totaled ¥158 million, down 39.8% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥144 million, down 57.5% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue increased, while orders received and the order backlog declined significantly. New orders and the accumulation of future revenue continue to weaken relative to recent revenue. - FY2023-Q2Revenue increased, but orders received and the order backlog continued to declineAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥151 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 21.5% year on year. Orders received totaled ¥72 million, down 64.0% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥158 million, down 57.7% from the end of the same period of the previous year.」
Revenue increased, while orders received and the order backlog were significantly below the same period of the previous year. New orders and the accumulation of future revenue continue to weaken relative to recent revenue. - FY2023-Q1Revenue increased, but orders received and the order backlog declinedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥70 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 11.2% year on year. Orders received totaled ¥43 million, down 66.7% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥210 million, down 42.4% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue increased, while orders received and the order backlog declined significantly. Compared with recent revenue, new orders and the accumulation of future revenue are weakening. - FY2022-Q3Revenue declined, orders received fell, and the order backlog continued to declineAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥218 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 26.3% year on year. Orders received totaled ¥263 million, down 11.0% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥340 million, down 16.1% from the end of the same period of the previous year.」
Revenue, orders received and the order backlog in the pharmaceutical clinical research support business all fell below the same period of the previous year. The scale of orders as a new source of revenue continues to weaken, following the previous quarter. - FY2022-Q2Revenue declined, orders received edged down, and the order backlog declinedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥124 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 39.8% year on year. Orders received totaled ¥202 million, down 1.0% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥374 million, down 7.6% from the end of the same period of the previous year.」
Revenue, orders received and the order backlog in the pharmaceutical clinical research support business all fell below the same period of the previous year. Following the increase in orders received and the order backlog seen in the previous quarter, the scale of orders is now weakening. - FY2022-Q1Revenue declined, but orders received increased and the order backlog edged upAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥63 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 58.7% year on year. Orders received totaled ¥131 million, up 36.7% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥364 million, up 4.0% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue declined, while orders received and the order backlog exceeded the same period of the previous year. Recent new orders and the accumulation of future revenue are increasing, but revenue recognition is weakening. - FY2021-Q3Orders received increased and the order backlog edged up, but revenue declined and the business remained in an operating lossAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥297 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 21.5% year on year. Orders received totaled ¥295 million, up 70.2% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥405 million, up 3.0% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, revenue declined 21.5% year on year, while orders received increased 70.2% and the order backlog increased 3.0%. The biological evaluation systems business as a whole posted an operating loss due to factors including a higher cost-of-sales ratio. - FY2021-Q2Orders received increased, but the order backlog declined and the business moved into an operating lossAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥206 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 10.3% year on year. Orders received totaled ¥204 million, up 210.4% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥404 million, down 6.7% from the end of the same period of the previous year.」
Revenue declined 10.3% year on year, while orders received increased 210.4%. However, the order backlog declined 6.7%, indicating a divergence between recent growth in orders and the accumulation of future revenue. - FY2021-Q1Orders received increased, but the order backlog declinedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥153 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 3.7% year on year. Orders received totaled ¥96 million, up 153.5% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥350 million, down 26.6% from the end of the same period of the previous year.」
Revenue declined 3.7% year on year, while orders received increased 153.5%. However, the order backlog declined 26.6%, indicating a divergence between recent growth in orders and the accumulation of future revenue. - FY2020Higher revenue and orders but lower order backlogAnnual report
「In the pharmaceutical clinical research support business, we recognized revenue of ¥442 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 36.5% from the previous fiscal year. Orders received totaled ¥251 million, up 26.6% from the previous fiscal year, while the order backlog at the end of the current consolidated fiscal year was ¥407 million, down 32.0% from the end of the previous fiscal year.」
Full-year revenue and orders received increased, while the order backlog declined. Recent revenue and new orders are making progress, but the accumulation of future revenue is weakening. - FY2020-Q3Orders received increased, but the order backlog continued to declineAnnual report
「In the pharmaceutical clinical research support business, we recognized revenue of ¥378 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 55.3% year on year. Orders received totaled ¥173 million, up 140.8% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥393 million, down 28.7% from the end of the same period of the previous year.」
Revenue and orders received were significantly higher than in the same period of the previous year, while the order backlog declined 28.7%. Recent orders and revenue are making progress, but the accumulation of future revenue is weakening. - FY2020-Q2Higher revenue and orders but lower order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥230 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes field, up 46.2% year on year. Orders received totaled ¥65 million, up 101.4% year on year, while the order backlog at the end of the second quarter of the current fiscal year was ¥433 million, down 27.6% from the end of the corresponding period of the previous year.」
Revenue and orders received exceeded the same period of the previous year, while the order backlog was down 27.6% from the end of the same period. New orders are making progress, but the accumulation of future revenue is weakening. - FY2020-Q1Higher revenue and orders but lower order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥158 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes field, up 90.3% year on year. Orders received totaled ¥38 million, up 114.5% year on year, while the order backlog at the end of the first quarter of the current fiscal year was ¥477 million, down 27.5% from the end of the corresponding period of the previous year.」
Revenue and orders received exceeded the corresponding period of the previous year, while the order backlog was down 27.5% from the end of the corresponding period of the previous year. New orders are recovering, but the accumulation of future revenue remains weak. - FY2019Higher revenue but lower orders and order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥324 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes field, up 9.4% year on year. Orders received totaled ¥198 million, down 24.4% year on year, while the order backlog at the end of the fiscal year was ¥598 million, down 17.4% from the end of the previous fiscal year.」
Although full-year revenue increased, orders received and the order backlog fell below the previous year. Revenue performance grew, but new orders and the accumulation of future revenue remain weak. - FY2019-Q3Further declines in orders and order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥243 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes field, down 0.6% year on year. Orders received totaled ¥72 million, down 64.9% year on year, while the order backlog at the end of the third quarter of the current fiscal year was ¥552 million, down 23.1% from the end of the corresponding period of the previous year.」
Revenue declined only 0.6% year on year, while orders received fell 64.9% and the order backlog fell 23.1%, indicating that the scale of orders in the pharmaceutical clinical research support business remains weak. - FY2019-Q2Decline in orders and order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥157 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes field, down 4.5% year on year. Orders received totaled ¥32 million, down 82.2% year on year, while the order backlog at the end of the second quarter of the current fiscal year was ¥599 million, down 22.8% from the end of the corresponding period of the previous year.」
Revenue, orders received and the order backlog all fell below the corresponding period of the previous year, with orders received declining particularly sharply. The scale of orders for this new core source of revenue remains weak. - FY2019-Q1Lower revenue, higher ordersAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recorded ¥83 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 23.6% year on year. Orders received totaled ¥17 million, up 24.3% year on year, while the order backlog at the end of the first quarter of the current fiscal year was ¥658 million, down 0.7% from the end of the corresponding period of the previous year.」
Revenue declined 23.6% year on year, while orders received increased 24.3% and the order backlog was virtually flat, down 0.7% from the end of the corresponding period of the previous year. Although revenue remains weak, there are signs of recovery in orders. - FY2018Declines in revenue, orders and order backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥296 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 7.6% year on year. Orders received totaled ¥262 million, down 22.4% year on year, while the order backlog at the end of the fiscal year was ¥724 million, down 4.4% from the end of the previous fiscal year.」
Revenue, orders received and the order backlog in the pharmaceutical clinical research support business all fell below the corresponding period of the previous year. The scale of the business as a new core source of revenue remains weak. - FY2018-Q3Slight declines in revenue and orders, slight increase in backlogAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥245 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 1.6% year on year. Orders received totaled ¥205 million, down 3.0% year on year, while the order backlog at the end of the third quarter of the current fiscal year was ¥718 million, up 2.2% from the end of the corresponding period of the previous year.」
Revenue and orders received edged down year on year, while the order backlog edged up to ¥718 million. Following the recovery in orders in the previous quarter, the scale of orders is now broadly flat. - FY2018-Q2AdvancedAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥165 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 11.5% year on year. Orders received totaled ¥183 million, up 71.4% year on year, while the order backlog at the end of the second quarter of the current fiscal year was ¥776 million, up 17.5% from the end of the corresponding period of the previous year.」
Revenue declined 11.5% year on year, while orders received rose 71.4% and the order backlog increased 17.5%, indicating numerical progress toward recovery from the decline in orders through the previous quarter. - FY2018-Q1Continued decline in orders receivedAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥109 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 1.6% year on year. Orders received totaled ¥14 million, down 63.2% year on year, while the order backlog at the end of the first quarter of the current fiscal year was ¥662 million, down 0.7% from the end of the corresponding period of the previous year.」
Revenue declined only 1.6% year on year, but orders received fell sharply by 63.2%, and the order backlog also edged down. The scale of orders for this new core source of revenue has weakened from the previous fiscal year. - FY2017-Q3Smaller scale and improved profitabilityAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥249 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, down 27.7% year on year. The business posted lower revenue but higher profit as the end of low-margin projects improved its profit margin. Orders received totaled ¥211 million, down 62.1% year on year, while the order backlog at the end of the third quarter of the current fiscal year was ¥702 million, down 14.0% from the end of the corresponding period of the previous year.」
Although revenue, orders received and the order backlog all fell below the corresponding period of the previous year, the end of low-margin projects improved the profit margin, resulting in higher profit despite lower revenue. - FY2017-Q1AdvancedAnnual report
「In the pharmaceutical clinical research support business, the company recorded ¥111 million in revenue from commissioned-service fees and other income, primarily for supporting physician-initiated clinical research in the diabetes and cardiovascular disease fields, up 23.8% year on year. Orders received totaled ¥38 million, up 47.1% year on year, while the order backlog at the end of the first quarter of the current fiscal year was ¥667 million, up 23.7% from the end of the corresponding period of the previous year.」
Revenue, orders received and the order backlog for physician-initiated clinical research support all exceeded the corresponding period of the previous year, indicating progress in the scale of the business as a new core source of revenue. - FY2016First statedAnnual report
「We are focusing on this as a business that could become a new earnings pillar.」
The business is positioned as an alternative source of earnings to food assessment testing, with contracts for physician-led clinical and epidemiological research being accumulated.